HRP20120286T1 - Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti - Google Patents
Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti Download PDFInfo
- Publication number
- HRP20120286T1 HRP20120286T1 HR20120286T HRP20120286T HRP20120286T1 HR P20120286 T1 HRP20120286 T1 HR P20120286T1 HR 20120286 T HR20120286 T HR 20120286T HR P20120286 T HRP20120286 T HR P20120286T HR P20120286 T1 HRP20120286 T1 HR P20120286T1
- Authority
- HR
- Croatia
- Prior art keywords
- physiologically acceptable
- combination
- acceptable salts
- glycopyrrolate
- pde
- Prior art date
Links
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title claims 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title claims 3
- 239000003112 inhibitor Substances 0.000 title claims 3
- 208000023504 respiratory system disease Diseases 0.000 title abstract 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 title 1
- 239000000812 cholinergic antagonist Substances 0.000 title 1
- 229940015042 glycopyrrolate Drugs 0.000 claims abstract 5
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960002586 roflumilast Drugs 0.000 claims abstract 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims abstract 3
- 208000006673 asthma Diseases 0.000 claims abstract 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims 3
- 229950005741 rolipram Drugs 0.000 claims 3
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 1
- 230000001078 anti-cholinergic effect Effects 0.000 abstract 1
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- 239000000168 bronchodilator agent Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002636 symptomatic treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54195504P | 2004-02-06 | 2004-02-06 | |
| PCT/EP2005/000651 WO2005074982A2 (en) | 2004-02-06 | 2005-01-24 | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120286T1 true HRP20120286T1 (hr) | 2012-04-30 |
Family
ID=34837532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120286T HRP20120286T1 (hr) | 2004-02-06 | 2012-03-30 | Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20050175547A1 (sl) |
| EP (1) | EP1713471B1 (sl) |
| JP (1) | JP4700014B2 (sl) |
| CN (2) | CN100512813C (sl) |
| AT (1) | ATE541570T1 (sl) |
| AU (1) | AU2005210084B2 (sl) |
| CA (1) | CA2550848C (sl) |
| CY (1) | CY1112968T1 (sl) |
| DK (1) | DK1713471T3 (sl) |
| ES (1) | ES2381116T3 (sl) |
| HK (1) | HK1096311A1 (sl) |
| HR (1) | HRP20120286T1 (sl) |
| NO (1) | NO337023B1 (sl) |
| NZ (1) | NZ548301A (sl) |
| PL (1) | PL1713471T3 (sl) |
| PT (1) | PT1713471E (sl) |
| RU (1) | RU2437658C2 (sl) |
| SI (1) | SI1713471T1 (sl) |
| WO (1) | WO2005074982A2 (sl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| EP1720543A1 (en) * | 2004-02-27 | 2006-11-15 | Altana Pharma AG | Roflumilast and glycopryrronium combination |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| EP1616567A1 (en) * | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| RU2008119323A (ru) * | 2005-10-19 | 2009-11-27 | Рэнбакси Лабораториз Лимитед (In) | Фармацевтические композиции мускаринового рецептора |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| CA2701956A1 (en) * | 2007-10-25 | 2009-04-30 | Merck Frosst Canada Ltd. | Combination therapy |
| US20100055045A1 (en) * | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| US20090215734A1 (en) * | 2008-02-26 | 2009-08-27 | Elevation Pharmaceuticals, Inc. | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| SG11201505835QA (en) * | 2013-01-28 | 2015-08-28 | Incozen Therapeutics Pvt Ltd | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide |
| PT2968312T (pt) * | 2013-03-15 | 2018-04-19 | Verona Pharma Plc | Combinação de fármacos |
| TW201542207A (zh) * | 2013-10-03 | 2015-11-16 | Otsuka Pharma Co Ltd | 嚴重氣喘治療劑 |
| CN104586841A (zh) * | 2013-10-30 | 2015-05-06 | 中国药科大学 | (3r,2’r)-格隆溴铵作为m3毒蕈碱性受体拮抗剂在制药中的用途 |
| CN104800192A (zh) * | 2014-01-27 | 2015-07-29 | 成都英诺新科技有限公司 | 一种罗氟司特吸入粉雾剂及制备方法 |
| RU2691110C2 (ru) * | 2017-11-20 | 2019-06-11 | Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) | Препарат для лечения заболеваний дыхательных путей у лошадей и способ его применения |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1046939C (zh) * | 1993-07-02 | 1999-12-01 | 比克·古尔顿·劳姆贝尔格化学公司 | 氟烷氧基取代的苯甲酰胺类及其制备方法和应用 |
| US6204285B1 (en) * | 1996-07-01 | 2001-03-20 | Sepracor Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate |
| US6384038B1 (en) * | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| AU7455498A (en) * | 1998-05-29 | 1999-12-20 | Citizen Watch Co. Ltd. | Method of subjecting ink jet printer to preuse treatment |
| NZ509489A (en) * | 1998-08-04 | 2002-10-25 | Jago Res A | Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil |
| SK284889B6 (sk) * | 1998-11-13 | 2006-02-02 | Jago Research Ag | Použitie stearátu horečnatého v suchých práškových formuláciách na inhaláciu |
| US6086914A (en) * | 1999-03-12 | 2000-07-11 | Weinstein; Robert E. | Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity |
| DE19921693A1 (de) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| US20040002548A1 (en) * | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| US20040028958A1 (en) * | 2002-06-18 | 2004-02-12 | Total Innovative Manufacturing Llc | Recyclable fire-resistant moldable batt and panels formed therefrom |
| DE19961300A1 (de) * | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| DE10007203A1 (de) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| GB0009583D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| GB0029903D0 (en) * | 2000-12-07 | 2001-01-24 | Arakis Ltd | Use of anti-muscarinic agents |
| US20040101483A1 (en) | 2001-03-30 | 2004-05-27 | Rudi Muller-Walz | Medical aerosol formulations |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| ATE347361T1 (de) * | 2001-05-25 | 2006-12-15 | Boehringer Ingelheim Pharma | Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen |
| CN1511042A (zh) * | 2001-05-25 | 2004-07-07 | 治疗阻塞性气道疾病的pde4抑制剂与抗胆碱能剂的组合 | |
| GB0118373D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| US7258118B2 (en) * | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| DE10230769A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
| US20040038958A1 (en) * | 2002-07-11 | 2004-02-26 | Chris Rundfeldt | Topical treatment of skin diseases |
| UA82323C2 (uk) * | 2002-08-09 | 2008-04-10 | Меда Фарма Гмбх & Ко. Кг | Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань |
| US20040053902A1 (en) * | 2002-09-13 | 2004-03-18 | Smith C. Steven | Novel composition and method for treatment of upper respiratory conditions |
| CA2519679C (en) * | 2003-03-28 | 2012-08-28 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| US20060189642A1 (en) | 2003-03-28 | 2006-08-24 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| US20060155491A1 (en) | 2003-07-11 | 2006-07-13 | Peter Bode | Frequency determination |
-
2005
- 2005-01-24 DK DK05701141.3T patent/DK1713471T3/da active
- 2005-01-24 NZ NZ548301A patent/NZ548301A/en unknown
- 2005-01-24 PL PL05701141T patent/PL1713471T3/pl unknown
- 2005-01-24 CN CNB200580002345XA patent/CN100512813C/zh not_active Expired - Fee Related
- 2005-01-24 EP EP05701141A patent/EP1713471B1/en active Active
- 2005-01-24 ES ES05701141T patent/ES2381116T3/es active Active
- 2005-01-24 PT PT05701141T patent/PT1713471E/pt unknown
- 2005-01-24 CN CN200910133531A patent/CN101518532A/zh active Pending
- 2005-01-24 SI SI200531513T patent/SI1713471T1/sl unknown
- 2005-01-24 WO PCT/EP2005/000651 patent/WO2005074982A2/en active Application Filing
- 2005-01-24 JP JP2006551762A patent/JP4700014B2/ja not_active Expired - Fee Related
- 2005-01-24 RU RU2006132040/15A patent/RU2437658C2/ru not_active Application Discontinuation
- 2005-01-24 AT AT05701141T patent/ATE541570T1/de active
- 2005-01-24 AU AU2005210084A patent/AU2005210084B2/en not_active Ceased
- 2005-01-24 CA CA2550848A patent/CA2550848C/en not_active Expired - Fee Related
- 2005-02-07 US US11/051,463 patent/US20050175547A1/en not_active Abandoned
-
2006
- 2006-07-13 US US11/485,486 patent/US20060251589A1/en not_active Abandoned
- 2006-08-31 NO NO20063880A patent/NO337023B1/no not_active IP Right Cessation
-
2007
- 2007-04-11 HK HK07103735.7A patent/HK1096311A1/xx not_active IP Right Cessation
-
2009
- 2009-02-03 US US12/365,003 patent/US8097605B2/en active Active
-
2012
- 2012-03-29 CY CY20121100323T patent/CY1112968T1/el unknown
- 2012-03-30 HR HR20120286T patent/HRP20120286T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1112968T1 (el) | 2016-04-13 |
| CN101518532A (zh) | 2009-09-02 |
| SI1713471T1 (sl) | 2012-07-31 |
| NZ548301A (en) | 2010-07-30 |
| WO2005074982A3 (en) | 2006-04-06 |
| US8097605B2 (en) | 2012-01-17 |
| CN100512813C (zh) | 2009-07-15 |
| AU2005210084A1 (en) | 2005-08-18 |
| CA2550848C (en) | 2013-02-26 |
| PT1713471E (pt) | 2012-04-10 |
| US20050175547A1 (en) | 2005-08-11 |
| ES2381116T3 (es) | 2012-05-23 |
| JP2007520507A (ja) | 2007-07-26 |
| EP1713471B1 (en) | 2012-01-18 |
| RU2006132040A (ru) | 2008-03-20 |
| US20090136429A1 (en) | 2009-05-28 |
| US20060251589A1 (en) | 2006-11-09 |
| PL1713471T3 (pl) | 2012-06-29 |
| DK1713471T3 (da) | 2012-05-14 |
| WO2005074982A2 (en) | 2005-08-18 |
| CN1909899A (zh) | 2007-02-07 |
| EP1713471A2 (en) | 2006-10-25 |
| JP4700014B2 (ja) | 2011-06-15 |
| RU2437658C2 (ru) | 2011-12-27 |
| HK1096311A1 (en) | 2007-06-01 |
| AU2005210084B2 (en) | 2010-06-24 |
| NO20063880L (no) | 2006-11-02 |
| CA2550848A1 (en) | 2005-08-18 |
| ATE541570T1 (de) | 2012-02-15 |
| NO337023B1 (no) | 2015-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120286T1 (hr) | Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti | |
| HRP20130835T1 (hr) | Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru | |
| AU2001295760A1 (en) | Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders | |
| CN101389313A (zh) | 用于吸入疗法的雾化抗生素 | |
| CA2550841A1 (en) | Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases | |
| HRP20130052T1 (hr) | Lijeäśenje respiratorne bolesti | |
| NZ550911A (en) | Treatment of bronchospasm with glycopyrrolate | |
| JP2018536014A (ja) | 液体ニコチン製剤 | |
| WO2007123955A3 (en) | Stable hydroalcoholic oral spray formulations and methods | |
| JP2007520507A5 (sl) | ||
| ES2303645T3 (es) | Composiciones para prevenir y tratar sintomas de tipo resfriado y gripe que comprenden cinc quelado. | |
| HRP20140707T1 (hr) | KOMBINACIJA ATORVASTATINA ILI SIMVASTATINA KAO INHIBITORA REDUKTAZE HMG-CoA S INHIBITOROM FOSFODIESTERAZE 4 KOJI JE ROFLUMILAST, ZA LIJEČENJE UPALNIH BOLESTI PLUĆA | |
| KR20070042917A (ko) | 소아 천식의 치료 | |
| DE60216588D1 (de) | Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen | |
| JP2012503668A5 (sl) | ||
| HRP20220929T3 (hr) | Sastav za inhalaciju koji sadrži aklidinij za liječenje astme | |
| JP2008533072A5 (sl) | ||
| NZ593695A (en) | Alkaloid aminoester derivatives and medicinal composition thereof | |
| HRP20050579A2 (hr) | Nove sinergistične kombinacije koje sadrže roflumilast i formoterol | |
| EP1583559B1 (en) | Compositions for prevention and treatment of cold and influenza-like symptoms comprising select mucoadhesive polymers | |
| JP2024516340A (ja) | Ｓａｒｓ－ｃｏｖ－２感染の後遺症の予防と治療のためのルミノール | |
| MEP54308A (en) | Aerosol formulation for inhalation comprising a tiotropium salt | |
| WO2010146394A1 (en) | Theobromine for the treatment of cough | |
| WO2007046113A3 (en) | Novel pharmaceutical composition comprising alkaloid and process thereof | |
| KR20050094810A (ko) | 로플루미래스트와 ｒ,ｒ-포르모테롤을 포함하는 상승작용성조합물 |